| Home | E-Submission | Sitemap | Editorial Office |  
Korean J Urol Oncol > Volume 1(4); 2003 > Article
The Korean Journal of Urological Oncology 2003;1(4): 371-375.
신세포암 환자에서 수상돌기세포의 배양 및 신세포암 세포주에 대한 항암면역효과: In vitro 연구
정한, 지영환, 김청수
가천의과대학교 비뇨기과교실, 1울산대학교 의과대학 비뇨기과학교실
Culture of Dendritic Cell from Patient with Renal Cell Carcinoma and Its Anti-tumor Immune Activity when Pulsed by Renal Cell Carcinoma Cell Line: In Vitro Study
Han Chung , Young Hwan Ji , Choung-Soo Kim
The Department of Urology, Gachon Medical School, Incheon and 1Ulsan University, College of Medicine, Asan Medical Center, Seoul, Korea
Published online: December 30, 2003.
Dendritic cells(DC) play a crucial role in the initiation of primary immune response and are known as an excellent adjuvant for anti-cancer immunity. In this study, we tried to obtain substantial numbers of dendritic cells from peripheral blood of patients with renal cell carcinoma and normal controls. We also investigated the anti-tumor immune response of dendritic cells pulsed by renal cell carcinoma cell line A498 in vitro. We compared with two different sources of dendritic cell in view of anti-tumor activity and maturation capacity of dendritic cells
Materials and Methods:
DC were generated by culturing plastic adherent mononuclear cells from the peripheral blood in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. Immature DC were cocultured with T-cells and pulsed by A498. MTT analysis was performed using the medium in which A498 only was cultured as control.
We could obtain 0.6⁣1.8x106 DC with phenotype typical of mature DC(CD14⁣, CD80⁢, CD83⁢) from the normal peripheral blood and patients with renal cell carcinoma. On T-cell proliferation assay, the number of T-cells increased in proportion to that of DC and when DC were pulsed by A498, the same phenomenon could be observed in normal control group. The number of T-cells not changed in DC from patients with renal cell carcinoma.
We could successfully obtain mature dendritic cells from the peripheral blood in patients with reanl cell carcinima. The data revealed indirectly that dendritic cells in patients with renal cell carcinoma treated with tumor lysate not enhance immune activity and not increases anti-cancer effect of T-cells. Further investigations including in-vivo study should be carried out to realize the effect of immunotherapy using dendritic cells against metastatic renal cell carcinoma. (Korean J Uro-Oncol 2003;1:371-375)
Key Words: Dendritic cell; Renal cell carcinoma
Editorial Office
Department of Urology, Chung-Ang University Hospital
102 Heukseok-ro, Dongjak-gu, Seoul 06973, Korea
Tel: +82-2-6299-1819   Fax: +82-2-6294-1406   E-mail: journal@kjuo.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Urological Oncology Society and The Korean Prostate Society.                 Developed in M2PI
Close layer
prev next